Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents (Q35842681)

10 August 2017

1 reference

title

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents (English)

1 reference

10 August 2017

0 references

1 reference

Jory R Baldridge

1

1 reference

10 August 2017

Patrick McGowan

2

1 reference

10 August 2017

Jay T Evans

3

1 reference

10 August 2017

Christopher Cluff

4

1 reference

10 August 2017

Sally Mossman

5

1 reference

10 August 2017

David Johnson

6

1 reference

10 August 2017

David Persing

7

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

1129-1138

1 reference

10 August 2017

7

1 reference

10 August 2017

TLR signaling pathways

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

A toll-like receptor that prevents infection by uropathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Endotoxin opens the Tollgates to innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Toll-like receptors as adjuvant receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Human beta-defensins and toll-like receptors in the upper airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

A prophylactic hepatitis B vaccine with a novel adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

The role of chemokines in linking innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Cytokines as a link between innate and adaptive antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1129

10.1517/14712598.4.7.1129

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference